Daily Stock Reporter is issuing a report on four stocks to watch. FBEC Worldwide Inc (OTCMKTS:FBEC) , Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Alexco Resource Corp. (USA) (NYSEMKT:AXU), and Centrus Energy Corp (NYSEMKT:LEU) have been added to our watchlist today. Continue reading to find out why. – To get daily alerts on top stocks on the OTCQB, OTCQX, Nasdaq, NYSE, and OTCBB, subscribe to our newsletter at DailyStockReporter.com.
FBEC Worldwide Inc (OTCMKTS:FBEC) recently amended its articles of incorporation in order to decrease its authorized shares of common stock, par value $0.001 per share, from 5,000,000,000 to 2,200,000,000. According to the company, this decrease was undertaken in order to tighten the capital structure of FBEC, and ease any shareholder concerns of material diluting events. During the last 30 days, shares of FBEC have traded between lows of $0.0141 and highs of $0.0297. In a recent press release, CEO of FBEC, Jason Spatafora, stated, “We have come an extraordinary way in a short amount of time with FBEC Worldwide Inc.’s product portfolio and partnerships. As we begin to scale our operations to truly make this a national lifestyle brand, we have to allocate funds accordingly to meet agreed upon measures related to demand and production to make this possible.”
Stay Informed and Up To Date On The Hottest Small Cap Nasdaq & OTC Plays. Get Them Here.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is a company that embraces the challenge of improving health by looking to bring innovative medicines targeting G protein-coupled receptors to patients. Arena’s focus is discovering, developing and commercializing drugs to address unmet medical needs, and BELVIQ® (lorcaserin HCl) is Arena’s first internally discovered drug approved for marketing. The company recently released their 4Q and full year 2015 financials. “Arena took a number of important steps in 2015, including initiating two Phase 2 clinical trials, partnering two of our programs, filing a new drug application and reducing our internal expenses,” stated Harry F. Hixson, Jr., Arena’s interim CEO. In the last week ARNA has notched increases of 35.97% seeing highs of $1.89 in Tuesday’s trading session.
Enjoy picks like this? Get These Alerts and More on top small cap Companies before They Rally, Text the phrase “StockAlerts” to 635-66
Alexco Resource Corp. (USA) (NYSEMKT:AXU) owns the Bellekeno silver mine, one of several mineral properties held by Alexco, which encompass substantially all of the historical Keno Hill Silver District, located in Canada’s Yukon Territory. On March 15th the company announced its’ will release its 4Q and year end 2015 result Wednesday March 23rd, 2016. In the last week of trading AXU has seen a pps hike of 74.62% from lows of $0.67 to highs of $1.17 in Tuesday’s trading day.
Stay Informed and Up To Date On The Hottest Small Cap Stocks; Free To Join Now
Centrus Energy Corp (NYSEMKT:LEU) is a trusted supplier of enriched uranium fuel for commercial nuclear power plants in the United States and around the world. The company yesterday 3/21/16 released 4Q and 2015 financials. “Our results for 2015 reflect our efforts to transform Centrus into the world’s most diversified nuclear fuel supplier,” quoted Daniel B. Poneman, Centrus president and CEO. “During the year we laid the groundwork for our future growth by amending our largest supply contract under mutually beneficial terms, while extending it through at least 2026. We also signed several new sales contracts to start rebuilding our order book.” LEU since Monday’s trading session is up 73.54% after hitting highs on Tuesday of $3.87.
Small Cap Stock Alerts: Get Them straight to your Cell Phone. To Receive Our Winning Small Cap Stock Alerts For Free, text “StockAlerts” to 63566.
www.DailyStockReporter.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals www.DailyStockReporter.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. You can subscribe to the www.DailyStockReporter.com newsletter and start receiving daily alerts. To subscribe by phone and receive messages directly to a mobile phone, text the phrase “StockAlerts” to 63566.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements.
EGM FIRM INC which owns www.DailyStockReporter.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release.
EGM FIRM INC, which owns www.DailyStockReporter.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice.
EGM FIRM INC which owns www.DailyStockReporter.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Contact Email: email@example.com
Eanings Review: Rambus Inc. (NASDAQ:RMBS), Revlon Inc (NYSE:REV)
Revlon Inc(NYSE:REV) +2.5% after-hours after announcing that President and CEO Fabian Garcia is stepping down “to pursue other opportunities,” and Executive Vice Chair Paul Meister will oversee operations on an interim basis.
REV also says it expects Q4 revenues of $785M, below $801M from the year-earlier quarter but ahead of analyst consensus estimate of $743M, and a $60M-$80M net loss for the quarter due to a charge related to the recent tax law changes.
REV expects Q4 adjusted EBITDA of $110M-$115M vs. $115M analyst consensus.
CFO Chris Peterson also denies rumors that the company is considering a material asset transfer that would shield assets from lenders.
Rambus Inc.(NASDAQ:RMBS) shares are down 5.5% aftermarket following Q4 results that beat revenue estimates and met on EPS. In-line Q1 guidance (under ASC 605 accounting change) has revenue from $94M to $100M (consensus: $100.38M) and EPS from $0.17 to $0.23 (consensus: $0.18).
Revenue breakdown: Royalties, $77.9M (+10% Y/Y); Product, $8.5M (-27%); Contract and other revenue, $15.5M (+2%); Licensing billings, $76.6M (+18%).Key metrics: Non-GAAP operating margin, 31%; total operating expenses, $67.5M; cash and equivalents, $172.2M; cash flow from operations, $33.3M.
ADTRAN, Inc. (NASDAQ:ADTN) Hits New Lows After Issuing disappointing Earnings Forecast
ADTRAN, Inc.(NASDAQ:ADTN) slumped to a 52-week low after forecasting below consensus guidance for Q4, revising its revenue estimate downward to $125M from $155M-$165M earlier and seeing EPS of ~$0.01; analysts had expected EPS of ~$0.14 and revenue of $161.2M.
ADTN also projects Q1 to come in at roughly the same as Q4, misses analyst consensus of $167.5M.
CEO Tom Stanton says Q4 results have been hurt by a merger-related review, which ADTN expects to be completed in 60-90 days, and slowdown in the spending at a domestic Tier 1 customer.
MKM Partners analyst Michael Genovese believes the customer is CenturyLink (CTL -2%), which accounted for 24% of ADTN’s total sales in 2016.
The analyst thinks the weakness should prove temporary, adding that ADTN’s performance likely will accelerate into 2019 as the company stands to benefit from 5G spending; MKM trims its ADTN target price to $25 from $27 but keeps its Buy rating.
Big IPO Coming: Celator Pharmaceuticals Inc(NASDAQ:CPXX), Moleculin Biotech’s (MBRX)
Today at 10am Eastern, Moleculin Biotech ticker symbol MBRX will debut on the Nasdaq stock exchange and is being considered as one of the most highly anticipated IPO’s of 2016 by the street. The excitement and anticipation is arising from many experts saying that Moleculin Biotech’s (MBRX) drug annamycin is far superior to Celator Pharmaceuticals Inc(NASDAQ:CPXX) drug daunorubicin.
CPXX which has been bought out by Jazz Pharmaceuticals plc – Ordinary Shares(NASDAQ:JAZZ) for $1.5 Billion Dollars last week, share price ran from $1.6 to $31 in 2 months. Moleculin Biotech’s share structure is a 1.5m public float Priced at $6.